The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis

Insights

Interferon-induced transmembrane protein 3 (IFITM3) limits viral disease by controlling cytokine production, not by blocking virus replication. IFITM3 restricts IL-6, preventing immune cell loss and promoting antiviral immunity.

Area of Science:

  • Immunology
  • Virology
  • Cell Biology

Background:

  • Interferon-induced transmembrane protein 3 (IFITM3) is an antiviral restriction factor known to inhibit viral entry.
  • Genetic variations in IFITM3 influence human susceptibility to viral diseases.
  • The precise mechanisms by which IFITM3 modulates pathogenesis beyond direct viral inhibition are not fully understood.

Purpose of the Study:

  • To investigate the role of IFITM3 in limiting herpesvirus pathogenesis using a murine model.
  • To elucidate how IFITM3 influences antiviral cellular immunity and cytokine production during infection.
  • To determine the impact of IFITM3 deficiency on immune cell populations and viral control.

Main Methods:

  • Utilized the murine cytomegalovirus (MCMV) infection model in wild-type and Ifitm3 knockout mice.
  • Assessed viral replication, pathogenesis, and immune cell dynamics (lymphopenia, NK cell death, T cell loss).
  • Quantified cytokine production, particularly IL-6, by myeloid cells in response to viral stimuli and TLR ligands (Poly(I:C), CpG).

Main Results:

  • IFITM3 limits MCMV-associated pathogenesis without directly inhibiting viral replication.
  • Mice lacking IFITM3 (Ifitm3-/-) exhibited restricted antiviral immunity, characterized by lymphopenia, apoptosis-independent NK cell death, and T cell loss.
  • Viral disease in Ifitm3-/- mice correlated with elevated IL-6 production, which IFITM3 was found to inhibit in myeloid cells.
  • While IL-6 can promote T cell responses, its uncontrolled production in Ifitm3-/- mice led to NK cell loss and impaired viral control.

Conclusions:

  • IFITM3 acts as a checkpoint regulator of antiviral immunity by controlling cytokine production, specifically inhibiting IL-6.
  • IFITM3's mechanism involves preserving immune cell populations (NK and T cells) and preventing excessive inflammation.
  • Targeting cytokines like IL-6 may be a therapeutic strategy for virus-infected individuals with compromised IFITM3 activity.